Current Report Filing (8-k)
December 08 2016 - 9:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): December 8, 2016
Marina
Biotech, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-13789
|
|
11-2658569
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
|
1176
Tourmaline Drive
Thousand
Oaks, CA
|
|
91320
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: 425-892-4322
N/A
Former
name or former address, if changed since last report
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
8.01 Other Events.
On
Thursday, December 8, 2016, Joseph W. Ramelli, the interim Chief Executive Officer of Marina Biotech, Inc., (the
“Company”), gave a presentation regarding the Company at the LD Micro Main Event at the Luxe Sunset
Boulevard Hotel in Los Angeles, California. A copy of the slide deck used in connection with the presentation is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Presentation
of Marina Biotech, Inc. at the LD Micro Main Event.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
|
Marina
Biotech, Inc.
|
|
|
|
|
|
December
8, 2016
|
By:
|
/s/
Joseph W. Ramelli
|
|
|
Name:
|
Joseph
W. Ramelli
|
|
|
Title:
|
Interim
CEO
|
EXHIBIT
INDEX
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Presentation
of Marina Biotech, Inc. at the LD Micro Main Event.
|